| 초록 |
Cancer is one of the diseases with the highest mortality rate. It is known that early diagnosis is very important for increasing the survival rate of cancer patients. Conventional diagnostic methods are expensive and time consuming. Furthermore, current tissue biopsy from patients is highly invasive. As an alternative approach, liquid biopsy can overcome these drawbacks. Various tumor markers including EGFR 19 and 21 are circulating through blood system in the form of proteins, genes. Therefore, the detection of those biomarkers by using liquid biopsy can be excellent solution as a novel cancer diagnostic. Especially, EGFR 19 deletion mutation gene is biomarker of non-small cell lung cancer, which is widely used for the clinical evaluation of cancer detection and progression. Here, we introduce a simple and non-invasive in-vitro diagnostic device called DhITACT-TR for detecting EGFR19 mutation. |
